PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company dedicated to enhancing surgical outcomes, has announced its participation in the prestigious 27th Annual H.C. Wainwright Global Investment Conference scheduled for September 8-9, 2025, at the Lotte New York Palace Hotel in New York City. Senior management will engage in a fireside chat with H.C. Wainwright Managing Director Brandon Folkes on September 8 from 11:30 AM to 12:00 PM ET. Additionally, the PolyPid team will conduct both virtual and in-person one-on-one investor meetings throughout the event. Interested investors can arrange meetings through H.C. Wainwright representatives or by contacting meetings@hcwco.com.

PolyPid is known for its innovative approach that leverages its proprietary Polymer-Lipid Encapsulation matriX (PLEX) technology, which allows for controlled and prolonged release of therapeutics. This technology is combined with Active Pharmaceutical Ingredients (APIs) to facilitate precise drug delivery over extended periods—ranging from days to months. The company is currently in the spotlight due to promising Phase 3 trial results for its lead product candidate, D-PLEX, which targets the prevention of abdominal colorectal surgical site infections. A New Drug Application (NDA) for D-PLEX is expected to be submitted in early 2026.

Beyond its lead product, PolyPid is developing an innovative pipeline that includes therapies for oncology, obesity, and diabetes, showcasing its commitment to addressing significant medical needs. For more information about PolyPid and its initiatives, visit their website at www.polypid.com and follow them on social media platforms like Twitter (X) and LinkedIn.

As PolyPid Ltd. (Nasdaq: PYPD) prepares for its participation in the 27th Annual H.C. Wainwright Global Investment Conference, there are strategic insights for investors to consider. Given the company's focus on enhancing surgical outcomes through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology, the upcoming conference could present key opportunities to gain insights into their progress and future developments.

PolyPid's D-PLEX product candidate has demonstrated promising phase 3 results for preventing surgical site infections in colorectal surgeries. The anticipated New Drug Application (NDA) submission in early 2026 could be a critical milestone, potentially driving stock value and investor interest. Investors should closely monitor discussions around this product during the fireside chat led by H.C. Wainwright's Brandon Folkes, as management may provide updates pertaining to regulatory timelines, commercialization strategies, and any partnerships that might be in the pipeline.

The company's diverse pipeline, which includes innovations in oncology, obesity, and diabetes, speaks to its capacity for growth and market expansion. Given the healthcare sector's increasing focus on targeted therapeutics, PolyPid's approach could be well-timed. Investors should look for updates on pipeline projects and how they may align with market needs.

Moreover, initiating one-on-one meetings with PolyPid's management could provide deeper insights into the company's operational strategies. Given the recent volatility in biotech stocks, engaging with company leadership may yield valuable information about risk management and future projections.

In conclusion, participating in the conference may aid investors in making informed decisions regarding PolyPid's potential, especially in light of upcoming regulatory milestones and its innovative pipeline. Keeping an eye on PolyPid’s developments through this event will be crucial for those considering investment in the company.